KVYO insider executes 10b5-1 trades: 15k sold, 15k acquired
Rhea-AI Filing Summary
A company officer completed multiple open-market transactions under a Rule 10b5-1 plan on 10/10/2025. The reporting person, the Chief Financial Officer, acquired 15,000 shares of Series B common stock and sold a total of 15,000 shares of Series A common stock in two blocks: 9,808 shares at a weighted-average price of $25.33 and 5,192 shares at a weighted-average price of $24.45. After these transactions the officer reports beneficial ownership of 481,719 shares of Series A common stock (including 439,032 unvested RSUs) and beneficial ownership of 393,476 derivative-linked shares (including 209,101 Series B shares and 184,375 unvested RSUs).
The filing discloses the trades were made pursuant to a 10b5-1 trading plan adopted on 8/16/2024, and notes that each Series B share converts into one Series A share. The reporting person signed the form via attorney-in-fact on 10/10/2025.
Positive
- Trades executed under a Rule 10b5-1 plan, providing procedural clarity and affirmative defense (plan dated 8/16/2024)
- Post-transaction beneficial ownership remains substantial: 481,719 Series A-equivalent shares including 439,032 unvested RSUs
Negative
- Officer sold 15,000 Series A shares (9,808 at a weighted-average $25.33 and 5,192 at $24.45), reducing immediate vested holdings
- Majority of reported holdings are unvested RSUs (439,032 Series A RSUs and 184,375 Series B RSUs), which are subject to vesting schedules and potential forfeiture
Insights
Officer used a pre-established plan to sell and buy company stock while retaining sizable equity exposure.
The reporting person executed sales and an acquisition under a Rule 10b5-1 trading plan adopted on 8/16/2024, which provides an affirmative defense against insider trading claims when properly implemented. The transaction mix shows partial liquidation of vested holdings alongside a conversion-capable purchase of 15,000 Series B shares, which convert one-for-one into Series A shares.
Dependency and risk center on ongoing vesting of RSUs and potential future conversion mechanics; monitor reported post-trade beneficial ownership and any future plan disclosures over the next 12 months for changes in insider ownership levels.
Sales were executed at weighted-average prices between $24.45 and $25.33, indicating modest liquidity exits.
The filing shows two sale blocks totaling 15,000 Series A shares sold at weighted-average prices in the $24.25–$25.85 range across multiple trades. The seller retained >480k beneficially owned shares including significant unvested RSUs, so the transactions represent a small percentage of reported holdings.
Watch for additional scheduled 10b5-1 activity or open-market trades in the next few quarters to assess whether these were routine plan-driven sales or part of a larger liquidity pattern.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Common Stock | 15,000 | $0.00 | -- |
| Conversion | Series A Common Stock | 15,000 | $0.00 | -- |
| Sale | Series A Common Stock | 9,808 | $25.33 | $248K |
| Sale | Series A Common Stock | 5,192 | $24.45 | $127K |
Footnotes (1)
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024. Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.93 to $25.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.25 to $24.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Consists of (i) 42,687 shares of Series A Common Stock and (ii) 439,032 unvested restricted stock units ("RSUs") awarded under the Issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement. Consists of (i) 209,101 shares of Series B Common Stock and (ii) 184,375 unvested RSUs awarded under the Issuer's 2015 Stock Incentive Plan, each representing the contingent right to receive one share of Series B Common Stock upon vesting and settlement.
